<DOC>
	<DOCNO>NCT00071955</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Vaccines make person 's cancer cell may make body build immune response kill cancer cell . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood . PURPOSE : Phase II trial study effectiveness rituximab follow vaccine therapy sargramostim treat patient refractory progressive non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Vaccine Therapy Sargramostim After Rituximab Treating Patients With Refractory Progressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression-free survival patient refractory progressive follicular non-Hodgkin 's lymphoma treat immediate delay autologous immunoglobulin idiotype-KLH conjugate vaccine sargramostim rituximab ( group I II ) . - Determine immune response rate patient treat regimen ( group I , II , III ) . - Determine safety toxicity regimens patient ( group I , II , III ) . OUTLINE : This open-label , multicenter study patient previously register confirm ineligible randomization protocol Genitope-G2000-03 . Patients receive rituximab IV weekly 4 week . - Group I : The first 30 patient achieve maintain partial response ( PR ) well receive autologous immunoglobulin idiotype-KLH conjugate vaccine subcutaneously ( SC ) day 1 sargramostim SC day 1-4 begin 26 week last dose rituximab . Treatment repeat every 2 week 14 week ( 8 immunization ) . - Group II : All subsequent patient achieve PR well receive autologous immunoglobulin idiotype-KLH conjugate vaccine sargramostim SC group I begin 13 week last dose rituximab . - Group III : Patients eligible group I II , investigator 's opinion , suitable candidate immunization autologous immunoglobulin idiotype-KLH conjugate vaccine sargramostim SC receive treatment group I II , begin 1 year last ( fourth ) dose rituximab . In group , treatment continue absence unacceptable toxicity emergence illness may interfere study assessment . Patients follow initial response 8 week completion immunization every 12 week additional year . Thereafter , immunize patient follow every 6 month receipt first subsequent anti-lymphoma therapy . PROJECTED ACCRUAL : Up 120 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm follicular center cell nonHodgkin 's lymphoma Stage III IV disease time entry GenitopeG200003 At least 1 bidimensionally measurable lesion ( 1.5 cm X 1.5 cm ) radiography Previously register confirm ineligible randomization GenitopeG200003 fail achieve maintain complete partial response chemotherapy CT scan chest , abdomen , pelvis ( neck palpable disease ) Completed 8 course chemotherapy ( cyclophosphamide , vincristine , prednisone [ CVP ] ) per GenitopeG200003 No intervene therapy lymphoma ( i.e. , antibody , corticosteroid , cytotoxic ) CVP study entry No evidence transformation ( e.g. , rapid tumor growth increase lactic dehydrogenase ) No CNS involvement PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month last immunization series HIV negative No history autoimmune disease condition require treatment immunosuppressive agent , include corticosteroid No malignancy within past 2 year except nonbasal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy See Disease Characteristics At least 6 month since prior corticosteroid , include topical administration concurrent disease No concurrent chronic ( twice monthly ) corticosteroid ( include topical inhale ) Transient use ( prior CT scan ) optical solution allow Radiotherapy Prior radiotherapy 2 sit 13 week rituximab allow Surgery Not specify Other No concurrent participation therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>